Table 2.

Demographics, pathological features and follow-up characteristics of 327 differentiated thyroid carcinoma patients presenting concurrent lymphocytic thyroiditis (N = 70 patients) or not (N = 257 patients). The data were obtained using a multivariate regression analysis. IL =  interleukin; N =  absolute number of patients.

	Thyroiditis
	Present	Absent	p-value
Demographic/Pathological/	N (%)	N (%)
Follow-up Factors
Gender
Female	66 (23.57)	214 (76.43)	0.013
Male	4 (8.51)	43 (91.49)
Ethnicity
White	60 (22.56)	206 (77.44)	0.475
Non-white	10 (18.18)	45 (81.82)
Smoking
smoker	15 (16.67)	75 (83.33)	0.175
non-smoker	55 (23.61)	178 (76.39)
Age
<40	32 (21.48)	117 (78.52)	0.978
≥40	38 (21.35)	140 (78.65)
Extrathyroidal invasion
Yes	28 (19.31)	117 (80.69)	0.377
No	38 (23.46)	124 (76.54)
pTNM stage
I	42 (22.46)	145 (77.54)	0.678
II	20 (26.32)	56 (73.68)
III	5 (18.52)	22 (81.48)
IV	3 (15.00)	17 (85.00)
Microcarcinoma
Yes	20 (27.03)	54 (72.97)	0.209
No	50 (20.16)	198 (79.84)
Differentiation grade
Well differentiated	54 (20.61)	208 (79.39)	0.282
Poorly differentiated	10 (28.57)	25 (71.43)
Lymph node metastasis
Yes	12 (14.12)	73 (85.88)	0.012
No	58 (24.17)	182 (75.83)
Distant metastasis
Yes	5 (14.71)	29 (85.29)	0.310
No	65 (22.26)	227 (77.74)
Familial cases of thyroid cancer
Yes	3 (33.33)	6 (66.67)	0.409
No	67 (21.07)	251 (78.93)
Preoperative Hashimoto's thyroiditis
Yes	7 (87.5)	1 (12.50)	<0.001
No	63 (20.00)	252 (80.00)
Metastasis during follow-up
Yes	2 (10.00)	18 (90.00)	0.267
No	68 (22.15)	239 (77.85)
Cumulative radioiodine dose
<250 mCi	18 (36.73)	31 (63.27)	0.005
≥250 mCi	6 (12.24)	43 (87.76)
IL-10 genotype
AA	13 (17.81)	60 (82.19)	0.039
AG/GG	28 (26.92)	76 (73.08)
IL-18 genotype
AA	18 (24.00)	57 (76.00)	0.969
AC/CC	26 (22.61)	89 (77.39)